Overview

Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of vildagliptin 50 mg bid compared to placebo as an add-on therapy to metformin in Chinese patients with T2DM inadequately controlled by metformin alone.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Metformin
Vildagliptin